We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaborat... Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single in-office intravitreal IVT injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust sustained treatment response reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor VEGF injections. Show more
- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD...
Table of Contents As filed with the Securities and Exchange Commission on March 4, 2024 Registration No. 333- UNITED STATES SECURITIES AND...
REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ___) Adverum Biotechnologies, Inc. (Name...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.55 | -9.87890376036 | 15.69 | 17.65 | 13.67 | 408010 | 14.94711817 | CS |
4 | -5.66 | -28.5858585859 | 19.8 | 20.9 | 13.67 | 1638449 | 17.5027587 | CS |
12 | 5.551 | 64.6291768541 | 8.589 | 29.8 | 8 | 2304713 | 18.44239401 | CS |
26 | -2.56 | -15.3293413174 | 16.7 | 29.8 | 7.4 | 1214327 | 17.33947144 | CS |
52 | 6.292 | 80.1732925586 | 7.848 | 29.8 | 6.81 | 804672 | 16.7996885 | CS |
156 | -85.06 | -85.7459677419 | 99.2 | 108.5 | 5.31 | 1222203 | 22.75291198 | CS |
260 | -37.96 | -72.8598848369 | 52.1 | 269.8 | 5.31 | 1210581 | 61.5045043 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions